Home > Insider Trading > Filing (0001209191-21-056062)

Filing Details

Accession Number:: 0001209191-21-056062
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2021-09-14 19:32:44
Reporting Period:: 2021-09-14

Accepted Time:: 2021-09-14 19:32:44
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1693415	Translate Bio Inc.	TBIO	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1354434	Jr C Ronald Renaud	C/O Translate Bio, Inc. 29 Hartwell Ave Lexington MA 02421	Chief Executive Officer	Yes	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2021-09-14	503,231	$38.00	No	4	S	Direct
Common Stock	Disposition	2021-09-14	409,913	$38.00	No	4	S	Indirect	By Ronald Renaud 2014 Irrevocable Family Trust
Common Stock	Disposition	2021-09-14	40,909	$38.00	No	4	S	Indirect	By Ronald C. Renaud, Jr. Trust - 2007

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Direct
No	4	S	Indirect	By Ronald Renaud 2014 Irrevocable Family Trust
No	4	S	Indirect	By Ronald C. Renaud, Jr. Trust - 2007

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (right to buy)	Disposition	2021-09-14	500,000	$0.00	500,000	$7.95
Common Stock	Stock Option (right to buy)	Disposition	2021-09-14	525,000	$0.00	525,000	$7.66
Common Stock	Stcok Option (right to buy)	Disposition	2021-09-14	325,000	$0.00	325,000	$23.82
Common Stock	Stock Option (right to buy)	Disposition	2021-09-14	1,071,009	$0.00	1,071,009	$7.39
Common Stock	Stock Option (right to buy)	Disposition	2021-09-14	89,996	$0.00	89,996	$8.34

Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
2029-03-07	No	4	S	Direct
2030-03-02	No	4	S	Direct
2031-03-09	No	4	S	Direct
2027-12-21	No	4	S	Direct
2028-03-06	No	4	S	Direct

Footnotes

As of September 14, 2021, Issuer was acquired in a cash tender by an indirect subsidiary of Sanofi, a French societe anonyme at a purchase price of $38.00 per share (the "Tender Offer"), as described more fully in the Schedule 14D-9 filed by the Issuer on August 16, 2021.
Under the terms of the Tender Offer, Issuer outstanding stock options, if not vested became vested, and all Issuer stock options were converted into cash consideration at the amount of the difference between the exercise price of the option and the Tender Offer price of $38.00 per share.
This option was granted on March 8, 2019. This option will vest as to 25% of the shares on March 8, 2020, and in thirty-six equal monthly installments thereafter as to the remaining shares through March 8, 2023.
This option was granted on March 3, 2020. This option will vest as to 25% of the shares on March 3, 2021, and in thirty-six equal monthly installments thereafter as to the remaining shares through March 3, 2024.
This option was granted on March 9, 2021. This option will vest as to 25% of the shares on March 9, 2022, and in thirty-six equal monthly installments thereafter as to the remaining shares through March 9, 2025.
This option was granted on December 22, 2017. The shares underlying became fully vested on March 9, 2021.
This option was granted on March 7, 2018. The shares underlying the option are scheduled to vest over four years, with 25% of the shares vesting on March 7, 2019 and the remainder vesting in equal monthly installment through March 7, 2022.